Our Team

Dr. Dolev Rafaeli assumed the duties of President Chief Executive Officer, and vice-Chairman of the board on October 30, 2023. Dr. Rafaeli has over 30 years of experience in the healthcare, medical device, consumer and industrial services fields. He served as the President and CEO of Strata Skin Sciences between 2018-2021. He was a Member of the Board of Directors of the company that founded the XTRAC business (which was sold to Strata Skin Sciences in 2015), PhotoMedex Inc. (Nasdaq: PHMD), between 2011 and 2017. Under his management at PhotoMedex, he oversaw sales growth from $19 million to over $300 million, driven by increases in brand portfolio, distribution channels and M&A transactions, and the creation of the unique Direct-to-Consumer go-to-market strategies that drove that growth. He was President and CEO of Radiancy, a subsidiary of PhotoMedex, from 2006 to 2017. He also served as General Manager of Orbotech in China and Hong Kong, and held senior positions at Motorola. Dr. Rafaeli holds a Ph.D. in Business Administration from Century University, an MBA (with distinction) from Cornell University, a Masters Degree in Operations Management and a B.Sc. in Industrial Engineering and Management (both Summa Cum Laude) from the Technion Israel Institute of Technology.

Mr. Lesovitz serves as Chief Financial Officer of Strata Skin Sciences, having previously served as Controller. Prior to joining Strata, Mr. Lesovitz served as the head of finance at Encore Dermatology, Inc., a fully integrated pharmaceutical company specializing in Dermatology. Mr. Lesovitz also held various finance roles with Iroko Pharmaceuticals, LLC, a global pharmaceutical company that develops and commercializes products for responsible pain management. Mr. Lesovitz began his career at BDO, where he spent more than 4 years within the organization’s Audit Practice. Mr. Lesovitz graduated with a B.A. in Accounting from Villanova University. He is a Certified Public Accountant.

Shmuel Gov is the Company’s Chief Operating Officer managing the company operations, including Manufacturing, Field Service, R&D, QARA and Value Added Services (Call center and Reimbursement department). In addition to those responsibilities, he is also responsible for the business development and marketing functions and Clinical Support. He joined the Company in 2015 as Vice President and General Manager. He has over 25 years of experience in medical device manufacturing, logistics, and R&D. He holds degrees in electronics engineering and international business management.

Dr. Uri Geiger has served as Managing Partner of Accelmed, a private equity investment firm he co-founded in 2009 focused on medical device companies. He currently serves as Strata’s Chairman of the Board of Directors. Prior to founding Accelmed, Dr. Geiger served as the CEO of Exalenz Bioscience Ltd., a medical technology company, from May 2006 until December 2008. Prior to that, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components from 2001 until 2003. Dr. Geiger was also the founding partner of Dragon Variation Fund in 2000, one of Israel's first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of and significant experience in capital markets. Dr. Geiger was formerly an adjunct professor at Tel Aviv University's Recanati School of Business where he lectured on private equity and venture capital and authored the books "Startup Companies and Venture Capital" and "From Concept to Wall Street." He earned his doctorate from New York’s Columbia University Center for Law & Economics, where he majored in global equity markets. Uri Geiger brings extensive entrepreneurial, management and investment know-how having created and built many successful medical device enterprises. Dr. Geiger served as Chairman and Board member of over 30 medical device companies including a number of NASDAQ listed companies.

Shmuel (Samuel) Rubinstein became a director of the Company effective May 29, 2018. Mr. Rubinstein has served for over 20 years as the Chief Executive Officer and General Manager of Taro Pharmaceuticals Industries, a NASDAQ traded dermatology company. Under his management, Taro grew to become a multinational company with over 1,000 employees worldwide and turnover of close to $450 million. In 2003, Mr. Rubinstein received the Exceptional Industrialist award. During these years he also finished an International Marketing Course at the Wharton School of the University of Pennsylvania. Mr. Rubinstein serves as a board member in Clal Biotechnology Industries, Trima Pharma, Kamada, and KSDG. Previously on the board of Exalenz, Medison Biotech and is a consultant to Sol-Gel Pharma. Mr. Rubinstein is also a director at the Medical Research Fund near The Tel Aviv Sourasky Medical Center and The National Authority for Yiddish Culture. We believe Mr. Rubinstein's qualifications to serve on the Board of Directors include his wealth of knowledge and industry expertise in finance, investment banking, mergers and acquisitions, equity research and investment management experience in the dermatology industry.

Dr. Yaniv has more than 25 years of experience in the venture capital, pharmaceutical and MedTech industries. As a senior manager, skilled physician, and experienced board member, she possesses a highly developed combination of leadership, decision making and business skills. Dr. Yaniv has served as partner at Accelmed since 2012, and serves as a Director or a Chairperson of a few of Accelmed's Innovative portfolio companies. In 2020, Dr. Yaniv co-founded Almeda Ventures (TASE: AMDA) , and currently serves as the CEO of the fund.

Dr. Yaniv holds an MD degree from the Ben-Gurion University and an MBA from the Recanati Business School at Tel Aviv University.

Wayne Cafran was appointed to the Board on October 26, 2023. He is a retired Principal from Big Four public accounting and financial services firm KPMG LLP where he worked for more than 30 years in the healthcare industry. As a national leader for KPMG’s Internal Audit practice, he has deep experience with internal controls over financial reporting, enterprise risk assessments and regulatory compliance. An authentic and collaborative leader, Mr. Cafran gained the respect of executive leaders and boards for his integrity and the ability to make difficult decisions and navigate complex challenges.

Since retiring from KPMG in 2021, Mr. Cafran has been serving on the boards of EmblemHealth, a health and wellness company that provides insurance plans, primary and specialty care, and wellness solutions, as well as MedMinder, the leading fully integrated, end-to-end pharmacy, medication adherence and connected care solution for elderly and polypharmacy patients. These roles utilize Mr. Cafran’s experience, judgement, and executive talents for governance, compliance, and oversight.

Mr. Cafran was previously a Board Chair for a not-for-profit mental health/ addiction program called Liberation Programs. He is also currently providing management consulting services to health systems. Wayne is passionate about promoting diversity at all levels, he served as a Champion on KPMG’s African American Business Resources Group as well as KPMG’s Veterans Business Resource Group. He holds a BA in Political Science from Binghamton University and a Master of Public Administration in Health Finance from New York University. The Chairman recommended to the Nominating Committee that Mr. Cafran be approached for a seat on the board.